AR034771A1 - Formulacion vacunal potenciada por la combinacion de un adn con un antigeno - Google Patents

Formulacion vacunal potenciada por la combinacion de un adn con un antigeno

Info

Publication number
AR034771A1
AR034771A1 ARP020102614A AR034771A1 AR 034771 A1 AR034771 A1 AR 034771A1 AR P020102614 A ARP020102614 A AR P020102614A AR 034771 A1 AR034771 A1 AR 034771A1
Authority
AR
Argentina
Prior art keywords
antigen
components
potentiated
dna
combination
Prior art date
Application number
Other languages
English (en)
Inventor
Cabrera Santiago Duenas
Grillo Juan Morales
Lajonchere Ponce De Leon Liz Alvarez
Lasa Alexis Musacchio
Feyt Rolando Pajon
Rodriguez Ariel Vina
Obregon Julio C Alvarez
Rivero Nelson Acosta
Donato Gillian Martinez
Original Assignee
Ct Ingenieria Genetica Biotech
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ct Ingenieria Genetica Biotech filed Critical Ct Ingenieria Genetica Biotech
Publication of AR034771A1 publication Critical patent/AR034771A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Abstract

Formulación de antígenos vacunales, la cual contiene como componentes principales: a) uno o varios ADN que expresan una o varias proteínas en el individuo inmunizado y b) un antígeno viral en proporciones adecuadas. Un efecto potenciador ejerce al menos uno de los componentes sobre la respuesta inmune generada contra el otro. Nuevas formulaciones, minimizando el número de componentes que sean capaces de ampliar y potenciar el espectro de respuesta inmune contra diferentes entidades patogénicas (Virus Hepatitis B y Virus Hepatitis C) y de generar vacunas combinadas contra entidades patógenas. Estas formulaciones pueden ser aplicadas en la industria farmacéutica para uso profiláctico y/o terapéutico en humanos.
ARP020102614 2001-07-16 2002-07-12 Formulacion vacunal potenciada por la combinacion de un adn con un antigeno AR034771A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CU20010171A CU23244A1 (es) 2001-07-16 2001-07-16 Formulacion vacunal potenciada por la combinacion de un adn con un antigeno

Publications (1)

Publication Number Publication Date
AR034771A1 true AR034771A1 (es) 2004-03-17

Family

ID=40091632

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP020102614 AR034771A1 (es) 2001-07-16 2002-07-12 Formulacion vacunal potenciada por la combinacion de un adn con un antigeno

Country Status (16)

Country Link
US (2) US20040234543A1 (es)
EP (1) EP1417973B1 (es)
JP (1) JP4217611B2 (es)
KR (1) KR100905249B1 (es)
CN (1) CN1241644C (es)
AR (1) AR034771A1 (es)
AU (1) AU2002325783B2 (es)
BR (1) BR0211181A (es)
CA (1) CA2453260C (es)
CU (1) CU23244A1 (es)
ES (1) ES2393546T3 (es)
MX (1) MXPA04000431A (es)
MY (1) MY134885A (es)
RU (1) RU2294212C2 (es)
WO (1) WO2003007986A2 (es)
ZA (1) ZA200400286B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU23496A1 (es) * 2004-09-03 2010-02-23 Ct Ingenieria Genetica Biotech Composición vacunal contra el virus de la hepatitis c
EP1844142B1 (en) 2005-01-20 2015-08-12 Nature Technology Corporation Vectors and methods for genetic immunization
WO2008153733A2 (en) 2007-05-29 2008-12-18 Nature Technology Corporation Vectors and methods for genetic immunization
CN104830789A (zh) * 2015-05-05 2015-08-12 杨光华 基于hcv1抗原的dc细胞、靶向性免疫细胞群及其制备方法和用途

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2239245B (en) * 1989-12-18 1993-11-10 Wellcome Found Post-transfusional non-A non-B hepatitis viral polypeptides
EP0461863A1 (en) * 1990-06-12 1991-12-18 Immuno Japan Inc. Oligonucleotide primers, and their application for high-fidelity detection of non-A, non-B hepatitis virus
US7070790B1 (en) * 1993-06-29 2006-07-04 The United States Of America As Represented By The Department Of Health And Human Services Nucleotide and deduced amino acid sequences of the envelope 1 and core genes of isolates of hepatitis C virus and the use of reagents derived from these sequences in diagnostic methods and vaccines
US6689757B1 (en) * 1996-02-12 2004-02-10 M.L. Laboratories Plc Methods for vaccination and vaccines therefor
CU22642A1 (es) * 1996-12-12 2000-12-22 Ct Ingenieria Genetica Biotech Secuencia de adnc derivadas del genoma del virus de la hepatitis c y su uso
CN1044092C (zh) * 1997-02-26 1999-07-14 上海医科大学 抗原－抗体－重组dna复合型疫苗
FR2760367B1 (fr) * 1997-03-06 1999-04-30 Pasteur Merieux Serums Vacc Composition vaccinale destinee a la prevention ou au traitement des hepatites c
EP0980434B1 (en) * 1997-05-06 2009-07-29 Novartis Vaccines and Diagnostics, Inc. Intracellular production of hepatitis c e2 truncated polypeptid
US6153421A (en) * 1997-07-18 2000-11-28 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Cloned genomes of infectious hepatitis C viruses and uses thereof
GB9726555D0 (en) * 1997-12-16 1998-02-11 Smithkline Beecham Plc Vaccine
DE19915178A1 (de) * 1999-04-03 2000-10-05 Univ Mainz Johannes Gutenberg Hepatitis C Virus Zellkultursystem
DK1233782T3 (da) * 1999-12-01 2009-02-09 Novartis Vaccines & Diagnostic Fremkaldelse af HCV-specifikke antistoffer

Also Published As

Publication number Publication date
JP2004537552A (ja) 2004-12-16
BR0211181A (pt) 2004-08-10
EP1417973B1 (en) 2012-08-29
ES2393546T3 (es) 2012-12-26
KR100905249B1 (ko) 2009-06-29
WO2003007986A8 (es) 2004-04-29
CA2453260C (en) 2013-03-19
CN1529616A (zh) 2004-09-15
US8691234B2 (en) 2014-04-08
RU2294212C2 (ru) 2007-02-27
WO2003007986A2 (es) 2003-01-30
AU2002325783B2 (en) 2006-08-17
ZA200400286B (en) 2004-10-04
MXPA04000431A (es) 2004-03-18
CN1241644C (zh) 2006-02-15
US20040234543A1 (en) 2004-11-25
CU23244A1 (es) 2007-10-17
US20100316669A1 (en) 2010-12-16
EP1417973A2 (en) 2004-05-12
JP4217611B2 (ja) 2009-02-04
RU2004104357A (ru) 2005-07-10
CA2453260A1 (en) 2003-01-30
MY134885A (en) 2007-12-31
WO2003007986A3 (es) 2004-03-04
KR20040028924A (ko) 2004-04-03

Similar Documents

Publication Publication Date Title
DE60121136D1 (de) Proteasom-influenzavirus-impfstoffzusammensetzung
MX2023000411A (es) Vacuna combinada de sars-cov-2 e influenza.
EP1594536A4 (en) ADJUVANT INFLUENZA VACCINE
WO2006113214A3 (en) Vaccine against pandemic strains of influenza viruses
CY1113078T1 (el) Συνθεση πολυσθενους εμβολιου
IS4518A (is) Nýtt lyfjaform fyrir bóluefni
MX342639B (es) Virus de la influenza recombinantes de alta titulacion para vacunas y terapia genica.
HUP0101047A1 (hu) Kombinált vakcinakészítmények
ATE309821T1 (de) Influenzavirus-impfstoffzusammensetzung
ATE527281T1 (de) Impfstoffe gegen aids umfassend cmv/r nucleinsäurekonstrukte
ATE485056T1 (de) Verbesserte impfstoffe
CY1110290T1 (el) Εμβολιο χοιρειου κυκλοϊου και κοκκοϊου
ATE501726T1 (de) Zusammensetzung mit immunogenen mikroteilchen
BR112022014830A2 (pt) Formulações de vacina para coronavírus
GB2386072A (en) Novel vaccine
MX2018015361A (es) Formulacion de vacuna contra el vih.
WO2022140364A3 (en) African swine fever (asf) virus vaccines
MX2023003199A (es) Vacuna contra la enfermedad por coronavirus de 2019 (covid-19) basada en el virus de la parainfluenza 5 (piv5).
BR112023019301A2 (pt) Formulações de vacina de coronavírus
MX2007002659A (es) Composicion vacunal contra el virus de la hepatitis c.
AR021414A1 (es) Formulaciones conteniendo particulas semejantes a virus como inmunopotenciadores por via mucosal
AR034771A1 (es) Formulacion vacunal potenciada por la combinacion de un adn con un antigeno
WO2005012538A3 (en) Accelerated vaccination
ATE505482T1 (de) Impfstoff gegen infektiöses lachsanämievirus
UY31574A1 (es) Vacunas contra la malaria

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed, e.g., due to non-payment of fee